Oramed Pharmaceuticals (ORMP) Downgraded to Sell at ValuEngine

ValuEngine cut shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a research note published on Tuesday.

Separately, HC Wainwright reiterated a buy rating and set a $25.00 price objective on shares of Oramed Pharmaceuticals in a research report on Thursday, October 5th.

Oramed Pharmaceuticals (NASDAQ ORMP) traded down $0.77 during mid-day trading on Tuesday, reaching $7.94. 240,400 shares of the company were exchanged, compared to its average volume of 43,205. Oramed Pharmaceuticals has a twelve month low of $5.82 and a twelve month high of $11.34.

A number of hedge funds and other institutional investors have recently made changes to their positions in ORMP. Wells Fargo & Company MN increased its position in Oramed Pharmaceuticals by 4.4% in the 2nd quarter. Wells Fargo & Company MN now owns 14,725 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 625 shares during the period. Virtu KCG Holdings LLC acquired a new position in Oramed Pharmaceuticals in the 2nd quarter valued at approximately $125,000. Finally, Susquehanna International Group LLP acquired a new position in Oramed Pharmaceuticals in the 3rd quarter valued at approximately $185,000. Hedge funds and other institutional investors own 2.18% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Oramed Pharmaceuticals (ORMP) Downgraded to Sell at ValuEngine” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.com-unik.info/2017/12/06/oramed-pharmaceuticals-ormp-downgraded-to-sell-at-valuengine.html.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

What are top analysts saying about Oramed Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oramed Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit